Mandi Brown
Primary Care · Oklahoma City, OKNPI 1033156096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 33.1% of the total. 2025 is the largest year on record at $534, more than ten times the $46 reported in 2021.
Across 49 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$324
- AbbVie$292
- Lilly USA, LLC$84
- Novo Nordisk$69
- Pfizer$59
- Exact Sciences$33
- plus $116 from 6 others
What the payments were for
- Food & beverage$978100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $324 |
| AbbVie | 13 | $292 |
| Lilly USA, LLC | 5 | $84 |
| Novo Nordisk | 3 | $69 |
| Pfizer | 3 | $59 |
| Exact Sciences | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
How this compares
$978 in reported general payments places this provider in the 75th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,188 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $692 |
| Atorvastatin Calcium | 64 | $666 |
| Pravastatin Sodium | 17 | $665 |
| Allopurinol | 18 | $516 |
| Levothyroxine Sodium | 63 | $444 |
| Escitalopram Oxalate | 16 | $433 |
| Omeprazole | 27 | $420 |
| Gabapentin | 18 | $357 |
| Simvastatin | 21 | $323 |
| Terazosin Hcl | 14 | $301 |
| Lisinopril | 29 | $285 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $264 |
| Metoprolol Succinate | 12 | $223 |
| Metformin Hcl | 19 | $175 |
Paid to pharmacies, not to this prescriber.
Other primary care in Oklahoma City
- Misty DeanOklahoma City$6K
- Jessica KearneyOklahoma City$5K
- Erin OlmstedOklahoma City$3K
- Divya JoykuttyOklahoma City$3K
- Kathy SpeigelOklahoma City$1K
- Kimberly AllenOklahoma City$1K
- Thomas CookOklahoma City$792
- Krystal RachalOklahoma City$704
- Kendra BondOklahoma City$488
- Janice GuthrieOklahoma City$220
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.